Similar Papers

Paper Title
Journal
Date
Author
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Anita Kumar ...
Blood | VOL. 134
Anita Kumar, et. al.Anita Kumar ...
13 Nov 2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma
Alison J Moskowitz ...
Blood | VOL. 134
Alison J Moskowitz, et. al.Alison J Moskowitz ...
13 Nov 2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Niloufer Khan ... Helen Hancock
Blood | VOL. 134
Niloufer Khan, et. al.Niloufer Khan ... Helen Hancock
13 Nov 2019
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
Ranjana H Advani ... Alex F Herrera
Blood | VOL. 132
Ranjana H Advani, et. al.Ranjana H Advani ... Alex F Herrera
29 Nov 2018
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface.
Zohreh Mansoori Moghadam ... Philipp Henneke
Blood | VOL. -
Zohreh Mansoori Moghadam, et. al.Zohreh Mansoori Moghadam ... Philipp Henneke
03 Feb 2025
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD.
Michael C Zaiken ... Bruce R Blazar
Blood | VOL. -
Michael C Zaiken, et. al.Michael C Zaiken ... Bruce R Blazar
03 Feb 2025
How I approach pharmacological thromboprophylaxis in children.
Anthony A Sochet ... Neil A Goldenberg
Blood | VOL. -
Anthony A Sochet, et. al.Anthony A Sochet ... Neil A Goldenberg
03 Feb 2025
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.